TY - DATA T1 - Effects of fingolimod on astrocyte activation and glutamate transporter mRNA levels in the spinal cord during EAE. PY - 2017/03/08 AU - De-Hyung Lee AU - Silvia Seubert AU - Konstantin Huhn AU - Lukas Brecht AU - Caroline Rötger AU - Anne Waschbisch AU - Johannes Schlachetzki AU - Alice Klausmeyer AU - Arthur Melms AU - Stefan Wiese AU - Jürgen Winkler AU - Ralf A. Linker UR - https://plos.figshare.com/articles/figure/Effects_of_fingolimod_on_astrocyte_activation_and_glutamate_transporter_mRNA_levels_in_the_spinal_cord_during_EAE_/4734160 DO - 10.1371/journal.pone.0171552.g003 L4 - https://ndownloader.figshare.com/files/7740676 KW - fingolimod KW - glutamate transporters glutamate transporter KW - F 1P KW - SLC 1A KW - sphingosine -1-phosphate modulator KW - glutamate aspartate transporter KW - protein level KW - slc 1a SLC 1A KW - astroglial glutamate transporters KW - astrocyte cell culture KW - change expression levels KW - slc 1a mRNA KW - slc 1a N2 - (A, B) Representative GFAP staining of spinal cord cross sections from a mouse treated with fingolimod in a preventive setting and a sham treated control at the maximum of EAE. Note the reduced GFAP staining after fingolimod treatment. Bar = 100µm (C) Blinded quantification of GFAP immunreactivity as marker of astrocyte activation on spinal cord cross sections. (D) RT-PCR analysis of slc1a2 expression. (E) RT-PCR analysis of slc1a3 expression, n = 6–8 per group. The mRNA expression of a prophylactically treated mouse is set to 1 as reference. All data are given as mean ± SEM. Please note that data are compiled from separate experiments with different starting points of fingolimod application (d0, 11 or 25). The day (d) on the X axis indicates the start of treatment directly after immunization (d0, n = 6 mice per group), at the first sign of symptoms (d11, n = 6 mice per group) or at the early chronic phase of the disease (d25, n = 8 mice per group). Experiments were analysed at the maximum of disease (days 15 or 17 p.i., respectively) for treatment start on day 0 and 11 p.i. and in the later chronic phase of EAE (day 80 p.i.) after treatment start on day 25 p.i. * p < 0.05, ** p < 0.01; *** p < 0.001, Mann Whitney test. ER -